Home > PJ (current issue) > The Society / Daily News | Search

The Pharmaceutical Journal
Vol 272 No 7299 p621
15 May 2004


Society summary


Society appoints a project manager to support its devolution review

The Royal Pharmaceutical Society has appointed a project manager to help with the devolution review announced at the February Council meeting (PJ, 14 February, p197).

Michele Savage, a parliamentary affairs and policy specialist, will provide support for the steering group that will review the Society’s function, structure and ways of working to ensure that it can meet the needs of devolution.

Issues to be covered in the review include a framework for the devolution of functions within a Britain-wide organisation, requirements for governance and accountability, the scope, role of and the structures and processes for policy-making, and the structure and function of the Scottish Department and Welsh Executive and their relationships with the Council and the directorates.

Led by Lord Fraser of Carmyllie (chairman of the Statutory Committee), the steering group will include the current chairmen and vice-chairmen of the Society’s Scottish Department and Welsh Executive, members of Council, the Secretary and Registrar and a constitutional specialist with expertise in devolution.

The group is expected to complete its report before the end of the year. The report will form part of the Society’s strategy and business planning programme.

Ms Savage joined the Society on 10 May from the Association for Spina Bifida and Hydrocephalus, where she worked as a project co-ordinator. Before that, she spent two years as parliamentary affairs and policy manager for the Scottish Society for Autism. She has also worked for two members of Parliament and a member of the Scottish Parliament.

Ms Savage reports to Rob Darracott, Director of Corporate and Strategic Development at the Society. He says: “We are obviously pleased to welcome someone with Michele’s expertise to support our review. Her experience of different political settings will be invaluable in helping take this work forward.”

Back to Top


©The Pharmaceutical Journal